CUTR - Cutera: Gains Aren't Surprising After Acne Laser Therapy Cleared
- Cutera has had a great start to 2022, with shares up >50% on string FY21 results, FY22 guidance and approval for its acne therapy AviClear.
- The medical aesthetics company saw its share price devastated by the pandemic - the sector was particularly hard hit - but recovered rapidly.
- Cutera has grown revenues in every year since 2012 excepting COVID disrupted 2020, and hasn't factored in AviClear revenues into its 2022 guidance.
- Analysts appear to have been caught cold by the AviClear approval and are scrambling to raise price targets.
- Medical Aesthetics is a sector I favour and although I think there is risk in investing at the current price of $70 per share, if AviClear hits the ground running, a $1.5bn market cap oughtn't be out of reach.
For further details see:
Cutera: Gains Aren't Surprising After Acne Laser Therapy Cleared